Compare Ascendis Pharma A/S (ASND) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Lumen Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Lumen Technologies Inc trades at $6.74 (market cap $6.93B). The key difference: Ascendis Pharma A/S is far larger — about 2.6× Lumen Technologies Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LUMN | |
|---|---|---|
Market Cap | $17.74B | $6.93B |
Sector | Health | Media |
52-Week High | $277.18 | $11.83 |
52-Week Low | $163.32 | $3.70 |
Enterprise Value | $18.11B | $18.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LUMN trades at $6.73, down 0.3% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$1.74B for 2025, though revenue remains substantial at $12.40B. Recent news highlights the acquisition of Alkira to bolster AI-era networking capabilities and cost-saving initiatives targeting $1B annually by 2027. Debt levels are high at $17.49B long-term, but leverage is trending downward.
The outlook is mixed: positive catalysts include strategic acquisitions and cost reductions, but persistent losses and high debt pose significant risks. Analyst consensus is cautious with a Hold rating predominating, though the $8.25 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
